Schwab Charles Investment Management Inc. boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.5% during the first quarter, Holdings Channel reports. The firm owned 4,404,045 shares of the biopharmaceutical company’s stock after buying an additional 150,318 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Gilead Sciences were worth $299,123,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Rockland Trust Co. raised its stake in Gilead Sciences by 16.7% in the first quarter. Rockland Trust Co. now owns 178,245 shares of the biopharmaceutical company’s stock worth $12,106,000 after buying an additional 25,551 shares during the last quarter. Linscomb & Williams Inc. raised its stake in Gilead Sciences by 3.0% in the first quarter. Linscomb & Williams Inc. now owns 5,275 shares of the biopharmaceutical company’s stock worth $358,000 after buying an additional 154 shares during the last quarter. Berkshire Asset Management LLC PA bought a new stake in Gilead Sciences during the first quarter worth about $270,000. Sigma Planning Corp raised its stake in Gilead Sciences by 7.7% in the first quarter. Sigma Planning Corp now owns 40,168 shares of the biopharmaceutical company’s stock worth $2,728,000 after buying an additional 2,889 shares during the last quarter. Finally, Hollencrest Securities LLC raised its stake in Gilead Sciences by 119.8% in the first quarter. Hollencrest Securities LLC now owns 7,723 shares of the biopharmaceutical company’s stock worth $525,000 after buying an additional 4,210 shares during the last quarter. 74.06% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences, Inc. (GILD) traded down 1.039% during trading on Friday, reaching $71.945. 2,036,270 shares of the company’s stock were exchanged. The company has a market capitalization of $93.95 billion, a PE ratio of 7.814 and a beta of 1.21. The company’s 50-day moving average is $72.31 and its 200-day moving average is $68.76. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $82.10.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. Gilead Sciences’s revenue for the quarter was down 8.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.08 earnings per share. Equities research analysts expect that Gilead Sciences, Inc. will post $8.76 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.86%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.

TRADEMARK VIOLATION NOTICE: This article was posted by Watch List News and is the property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.watchlistnews.com/gilead-sciences-inc-gild-shares-bought-by-schwab-charles-investment-management-inc/1475283.html.

A number of research analysts have weighed in on the company. Cowen and Company reissued a “buy” rating and set a $100.00 price target on shares of Gilead Sciences in a research note on Monday, April 17th. Stifel Nicolaus reissued a “buy” rating and set a $87.00 price target on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $76.00 price target on the stock in a research note on Tuesday, May 2nd. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.88 price target on the stock. in a research note on Tuesday, April 25th. Finally, Piper Jaffray Companies reissued a “buy” rating on shares of Gilead Sciences in a research note on Friday, April 21st. Twelve analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $80.31.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at $227,197,799. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the completion of the sale, the executive vice president now directly owns 137,488 shares of the company’s stock, valued at approximately $10,174,112. The disclosure for this sale can be found here. Over the last three months, insiders have sold 206,666 shares of company stock valued at $15,223,184. 1.30% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.